Antibody cell line development: screening clones on product quality as well as titre, how cell line screening is staged, and the clonality and stability evidence a line must carry

Building the screen

1. Screen on quality from the first cut. Aggregation, charge variants, glycan profile and fragmentation vary between clones and are not correctable downstream without cost. Bringing analytical screening forward into the early funnel eliminates unusable clones before the expensive stages rather than after them.
2. Titre in the right format. Productivity measured in a small static format does not predict productivity in a fed-batch process, and clones reorder between the two. Screen in a format that resembles the intended process as early as the funnel allows, or the ranking you carry forward is the wrong ranking.
3. Clonality evidence at deposition. The line must be shown to derive from a single cell, with evidence captured at the time, typically imaging of the deposition event retained as a record. Regulators ask for this directly, and it cannot be reconstructed later.
4. Stability over the required generations. Expression and product quality are assessed over a generation number that covers the intended manufacturing scale with margin. A clone that drifts in glycan profile over the generations a campaign needs is a clone that has to be found now rather than at scale.
5. Bank and document before you scale. A research bank with identity, sterility, mycoplasma and adventitious agent testing, plus the process description, is what lets the programme continue if anything changes. Establish where the backup sits and who may access it.

Host lines and the licences underneath

Host lines, selection systems and expression technologies used in this field are licensed, and the terms travel with your programme rather than staying with the provider. Milestone and royalty obligations attached to a host line are a real cost and are invisible in the development quote.

Get the complete licence position in writing at contracting. This is the single most common unpleasant discovery in antibody cell line projects and it arrives at the worst possible moment, which is when the programme is succeeding.

What to receive at the end

The banked line with its testing package, the clonality evidence, the stability data over the agreed generations, the process description sufficient to run it elsewhere, and the analytical results that supported clone selection. Anything less is a line you cannot move.

Ask specifically for the data on clones that were rejected and why. It is the cheapest insight available into whether the funnel was selecting on the things you care about.

Common questions

Why screen antibody clones on product quality?

Because aggregation, charge variants and glycan profile vary between clones, are expensive to correct downstream, and are not predicted by titre. A titre-only funnel reliably produces high producers that cannot be used.

What clonality evidence is expected?

Evidence captured at the time of single cell deposition, usually imaging retained as a record, showing the line derives from one cell. It is asked for directly and cannot be reconstructed afterwards.

How many generations should stability cover?

Enough to cover the intended manufacturing scale with a margin, since expression and quality attributes can drift. A study that stops short of what the process needs will have to be repeated.

Do host cell line licences affect my programme?

Usually yes. Host lines and expression systems carry terms including milestones or royalties that attach to the programme rather than the provider. Get the full position in writing before development starts.

Browse by service class

• Compare Gene synthesis on advertised prices